Tuesday, June 6, 2023

Prejex Inc., a spin-off of Germany-based Prejex GMBH has entered into an agreement with Polybond, headed by Mr Adit Rathi of Rathi Group to manufacture needle-less injections. This partnership has enabled shifting of the manufacturing capabilities of the German company from Berlin to Pune, for global distribution. The Prejex-Polybond factory will make needle-less injections for the entire world.

The efforts of Mr. Niraj Khinvasara, CIO, World Trade Center, Pune, and Mr. Sagar Chordia, Chairman, World Trade Center Pune presented to Prejex a data-based analysis highlighting Pune as an industrial hub which includes over 250 German firms. The presentation focused on the decision of Mr. Maarten Stuut, MD of Prejex GMBH, and Mr. Harold Gerrits, Director of Global Sales and Distribution, to select India—especially Pune—as their preferred destination.

This FDI influx is a massive boost for Pune’s industrial capacity. India has a healthy medical ecosystem, which is a win-win situation for all the parties involved. World-class manufacturing units and long experience in medical manufacturing via subsidy company Eversure made Mr. Rathi the perfect partner for this revolutionary venture.


Prejex’s New Drug Delivery System (NDDS) via needle-less injections is a cutting-edge innovation that the medical world has long been waiting for. Prejex provides a solution to a variety of issues that professionals face in day-to-day operations. Syringes and disposable needles are major contributors to toxic waste and their disposal cost is sky-rocketing. Trypanophobia (fear of needles) is a common factor leading to the reluctance of patients in drawing of blood and receiving vaccines or intravenous fluids.

With Prejex’s entry, the pain factor is eliminated as the medicine is delivered subcutaneously through the skin which is an effective and reliable system. It also negates cross-contamination, ensuring the highest levels of safety and hygiene for doctors and patients alike. Being easy to use, even the patient can self-inject, reducing visits to the clinic and making healthcare more cost-effective. It is also highly convenient for customized doses and application of a variety of drugs. The shelf life of the drugs is considerably increased due to the novel COC polymer syringes and plasticizer. Besides, it drastically cuts down on the use of disposable syringes, most of which are used by diabetic patients, thus adding to the sustainability factor (about 5.5% of the global population or 422 million people are diabetic).

New Drug Delivery System (NDDS) via needle-less injections is an exciting and revolutionary concept in pharma since it contributes to increased medication margins/revenues. Moreover, innovations in supply chain and delivery system make Prejex a pharmaceutical company with a superior edge.